Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et fase 3 -forsøg til vurdering af CYB003 i større depressiv lidelse (EMBRACE)

30. oktober 2026 opdateret af: Cybin IRL Limited

En effektivitet og sikkerhed, fase III, multicenter, dobbeltblind, randomiseret kontrolleret undersøgelse, der sammenligner 2 aktive doser af CYB003 og placebo hos støtteberettigede deltagere med større depressiv lidelse

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

330

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
        • Rekruttering
        • Royal Prince Alfred Hospital
        • Ledende efterforsker:
          • Nicholas Glozier
    • Queensland
      • Maroochydore, Queensland, Australien, 4558
        • Rekruttering
        • Thompson Brain & Mind Healthcare (TBMH)
        • Ledende efterforsker:
          • Adem Can
        • Kontakt:
        • Kontakt:
    • Victoria
      • Melbourne, Victoria, Australien, 3004
      • Melbourne, Victoria, Australien, 3053
      • Notting Hill, Victoria, Australien, 3168
        • Rekruttering
        • Monash University - Notting Hill
        • Kontakt:
        • Ledende efterforsker:
          • Paul Liknaitzky
      • Cambridge, Det Forenede Kongerige, CB1 2EU
        • Rekruttering
        • Cambridge University Hospital NHS
        • Ledende efterforsker:
          • Liliana Galindo
        • Kontakt:
        • Kontakt:
      • Doncaster, Det Forenede Kongerige, DN4 8QN
        • Rekruttering
        • Clerkenwell Health - Doncaster
        • Ledende efterforsker:
          • Paul Morrison
        • Kontakt:
      • Edinburgh, Det Forenede Kongerige, EH16 4TJ
        • Ikke rekrutterer endnu
        • NHS Research Scotland
        • Ledende efterforsker:
          • Donald MacIntyre
        • Kontakt:
      • Glasgow, Det Forenede Kongerige, G51 4TF
      • Liverpool, Det Forenede Kongerige, L7 8XP
        • Ikke rekrutterer endnu
        • Royal Liverpool Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Fabian Devlin
      • London, Det Forenede Kongerige, EC2Y 8EA
        • Rekruttering
        • St Pancras Clinical Research
        • Ledende efterforsker:
          • Martin Johnson
        • Kontakt:
      • London, Det Forenede Kongerige, W1U 6RP
      • London, Det Forenede Kongerige, W1G9 RU
        • Rekruttering
        • Re:Cognition Health
        • Ledende efterforsker:
          • Dimitrios Paschos
        • Kontakt:
          • Telefonnummer: +44-0800-802-1030
      • London, Det Forenede Kongerige, SE5 9RS
      • London, Det Forenede Kongerige, W1G 8DR
        • Trukket tilbage
        • Clerkenwell Health - Welbeck Street
      • Newcastle upon Tyne, Det Forenede Kongerige, NE4 5PL
      • Reading, Det Forenede Kongerige, RG7 8PA
        • Rekruttering
        • Ascend Clinical Research
        • Ledende efterforsker:
          • Pamela Walters
        • Kontakt:
      • Sheffield, Det Forenede Kongerige, S4 7QQ
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35209
        • Rekruttering
        • UAB Psychiatry and Behavioral Neurology
        • Kontakt:
        • Ledende efterforsker:
          • Peter Hendricks
        • Kontakt:
    • Arizona
      • Gilbert, Arizona, Forenede Stater, 85234
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72204
        • Trukket tilbage
        • Pillar Clinical Research - Little Rock
    • California
      • Glendale, California, Forenede Stater, 91206
        • Rekruttering
        • Behavioral Research Specialists, LLC
        • Ledende efterforsker:
          • Jesse Carr
        • Kontakt:
      • Imperial, California, Forenede Stater, 92251
        • Trukket tilbage
        • Sun Valley Research Center
      • Los Angeles, California, Forenede Stater, 90025
        • Rekruttering
        • CalNeuro Research Group
        • Ledende efterforsker:
          • Alexander Bystritsky
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90025
      • Orange, California, Forenede Stater, 92868
        • Rekruttering
        • NRC Research Institute
        • Kontakt:
        • Ledende efterforsker:
          • Daniel Chueh
      • Orange, California, Forenede Stater, 92866
        • Rekruttering
        • ATP Clinical Research
        • Ledende efterforsker:
          • Gustavo Alva
        • Kontakt:
      • San Juan Capistrano, California, Forenede Stater, 92675
        • Ikke rekrutterer endnu
        • Inland Psychiatric Medical Group Inc (IPMG Research)
        • Ledende efterforsker:
          • Neelima Kunam
        • Kontakt:
      • Santa Monica, California, Forenede Stater, 90404
        • Rekruttering
        • Psychedelic Science Institute
        • Ledende efterforsker:
          • Keith Heinzerling
        • Kontakt:
      • Stanford, California, Forenede Stater, 94305
        • Trukket tilbage
        • Stanford University
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06511
        • Rekruttering
        • Yale School of Medicine - Yale Program for Psychedelic Science
        • Ledende efterforsker:
          • Ben Kelmendi
        • Kontakt:
          • Daidre Chamberlain
          • Telefonnummer: 203-693-1591
          • E-mail: enact@yale.edu
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32256
        • Rekruttering
        • CNS Healthcare
        • Kontakt:
          • Telefonnummer: 904-281-5757
        • Ledende efterforsker:
          • John Mark Joyce
      • Maitland, Florida, Forenede Stater, 32751
        • Rekruttering
        • Accel Research Sites - Maitland
        • Kontakt:
          • Telefonnummer: 407-644-1165
        • Ledende efterforsker:
          • Andrea Marrafino
      • Naples, Florida, Forenede Stater, 34105
        • Rekruttering
        • Aqualane Clinical Research
        • Ledende efterforsker:
          • Matthew Baker
        • Kontakt:
      • Tampa, Florida, Forenede Stater, 33634
        • Rekruttering
        • K2 Medical Research Tampa
        • Ledende efterforsker:
          • Kelley Wilson
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30329
        • Trukket tilbage
        • Emory University Dept of Psychiatry and Behavioral Studies
      • Marietta, Georgia, Forenede Stater, 30060
        • Rekruttering
        • Psych Atlanta
        • Ledende efterforsker:
          • Michael Banov
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Rekruttering
        • Rush University
        • Ledende efterforsker:
          • Joshua Eloge
        • Kontakt:
    • Louisiana
      • Marrero, Louisiana, Forenede Stater, 70006
        • Trukket tilbage
        • Tandem Clinical Research
      • New Orleans, Louisiana, Forenede Stater, 70115
        • Rekruttering
        • Atlas Psychiatry
        • Kontakt:
        • Ledende efterforsker:
          • Nicholas Pejic
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21224
        • Trukket tilbage
        • Johns Hopkins Medicine
      • Rockville, Maryland, Forenede Stater, 20850
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02116
        • Rekruttering
        • Adams Clinical Boston
        • Ledende efterforsker:
          • Darin Dougherty
        • Kontakt:
      • Watertown, Massachusetts, Forenede Stater, 02472
        • Rekruttering
        • Adams Clinical Watertown
        • Ledende efterforsker:
          • Stephanie Ellickson
        • Kontakt:
    • Minnesota
      • Eden Prairie, Minnesota, Forenede Stater, 55347
        • Rekruttering
        • Institute for Integrative Therapies
        • Ledende efterforsker:
          • Manoj Doss
        • Kontakt:
      • Golden Valley, Minnesota, Forenede Stater, 55427
        • Ikke rekrutterer endnu
        • The Remedy Mental Health
        • Kontakt:
        • Ledende efterforsker:
          • Wayne Bentham
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89119
        • Rekruttering
        • Redbird Research, LLC
        • Ledende efterforsker:
          • Jelena Kunovac
        • Kontakt:
    • New Jersey
      • Toms River, New Jersey, Forenede Stater, 08755
        • Rekruttering
        • Bio Behavioral Health
        • Kontakt:
        • Ledende efterforsker:
          • Ashok Patel
    • New York
      • New York, New York, Forenede Stater, 10032
        • Ikke rekrutterer endnu
        • New York State Psychiatric Institute
        • Ledende efterforsker:
          • Natalie Gukasyan
        • Kontakt:
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Adams Clinical Harlem
        • Ledende efterforsker:
          • Rachel Noone
        • Kontakt:
      • The Bronx, New York, Forenede Stater, 10461
        • Rekruttering
        • Adams Clinical Bronx
        • Ledende efterforsker:
          • Shama Farooq
        • Kontakt:
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73112
        • Trukket tilbage
        • SP Research PLLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Adams Clinical Philadelphia
        • Ledende efterforsker:
          • Cassie Blanchard
        • Kontakt:
      • Philadelphia, Pennsylvania, Forenede Stater, 19462
        • Rekruttering
        • Flourish Research Philadelphia
        • Ledende efterforsker:
          • Rachna Saralkar
        • Kontakt:
          • Telefonnummer: 215-614-5606
    • Texas
      • Austin, Texas, Forenede Stater, 78737
        • Trukket tilbage
        • Austin Clinical Trial Partners
      • DeSoto, Texas, Forenede Stater, 75115
        • Rekruttering
        • Adams Clinical Dallas
        • Ledende efterforsker:
          • Rajinder Shiwach
        • Kontakt:
      • Fort Worth, Texas, Forenede Stater, 76104
        • Trukket tilbage
        • North Texas Clinical Trials
      • Houston, Texas, Forenede Stater, 77046
        • Rekruttering
        • Brain Health Consultants and TMS Center
        • Ledende efterforsker:
          • Lauren Marangell
        • Kontakt:
      • San Antonio, Texas, Forenede Stater, 78229
    • Washington
      • Everett, Washington, Forenede Stater, 98201
        • Ikke rekrutterer endnu
        • Core Clinical Research
        • Kontakt:
        • Ledende efterforsker:
          • James Knutson
      • Seattle, Washington, Forenede Stater, 98104
        • Rekruttering
        • Seattle Neuropsychiatric Treatment Center
        • Ledende efterforsker:
          • Rebecca Allen
        • Kontakt:
      • Athens, Grækenland, 12462
        • Rekruttering
        • Attikon University Hospital
        • Ledende efterforsker:
          • Nikolaos Smyrnis
        • Kontakt:
      • Athens, Grækenland, 11528
        • Rekruttering
        • Eginitio Hospital
        • Ledende efterforsker:
          • Nikos Stefanis
        • Kontakt:
      • Thessaloniki, Grækenland, 56404
        • Rekruttering
        • Papageorgiou General Hospital
        • Ledende efterforsker:
          • Georgios Papazisis
        • Kontakt:
      • Dublin, Irland, D24 WK80
        • Rekruttering
        • Sheaf House - Tallaght Adult Mental Health Service
        • Ledende efterforsker:
          • John Kelly
        • Kontakt:
      • Galway, Irland, H91 VE03
        • Rekruttering
        • La Nua Day Hospital Mental Health Centre
        • Kontakt:
        • Ledende efterforsker:
          • Shane McInerney
      • Bialystok, Polen, 15-272
        • Trukket tilbage
        • Uniwersytecki Szpital Kliniczny W Białymstoku
      • Bydgoszcz, Polen, 85-133
        • Rekruttering
        • Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
        • Kontakt:
        • Ledende efterforsker:
          • Katarzyna Lachut
      • Gdansk, Polen, 80-546
        • Rekruttering
        • Centrum Badan Klinicznych PI-House Sp. z o.o
        • Kontakt:
        • Ledende efterforsker:
          • Hanna Badzio-Jagiello
      • Gdansk, Polen, 80-214
        • Ikke rekrutterer endnu
        • UCK
        • Ledende efterforsker:
          • Wieslaw Jerzy Cubala
        • Kontakt:
      • Warsaw, Polen, 02-957
        • Ikke rekrutterer endnu
        • Department of Pharmacology and Physiology of CNS
        • Ledende efterforsker:
          • Justyna Holka-Pokorska
      • Warsaw, Polen, 02-172
        • Rekruttering
        • MTZ Clinical Research Powered by Pratia
        • Ledende efterforsker:
          • Monika Gawlowicz
      • Prague, Tjekkiet
        • Ikke rekrutterer endnu
        • Institute of neuropsychiatric Care (INEP)
        • Ledende efterforsker:
          • Alexander Nawka
        • Kontakt:
      • Prague, Tjekkiet
        • Ikke rekrutterer endnu
        • Psyon s.r.o.
        • Ledende efterforsker:
          • Tomas Palenicek
        • Kontakt:
      • Předměstí, Tjekkiet
        • Ikke rekrutterer endnu
        • A-SHINE s.r.o.
        • Ledende efterforsker:
          • Lubos Janu
        • Kontakt:
      • Berlin, Tyskland, 10117
        • Ikke rekrutterer endnu
        • Charité Universitaetsmedizin Berlin
        • Ledende efterforsker:
          • Michael Koslowski
        • Kontakt:
      • Frankfurt am Main, Tyskland, 60528
        • Ikke rekrutterer endnu
        • University Hospital Frankfurt
        • Ledende efterforsker:
          • Andreas Reif
        • Kontakt:
      • Mannheim, Tyskland, 68159
        • Ikke rekrutterer endnu
        • Central Institute of Mental Health
        • Kontakt:
        • Ledende efterforsker:
          • Gerhard Grüender
    • Saarland
      • Homburg, Saarland, Tyskland, 66421
        • Ikke rekrutterer endnu
        • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
        • Ledende efterforsker:
          • Matthias Riemenschneider
        • Kontakt:
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Age18 to 85 years.
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Moderate to severe depression at Screening and Baseline, independently confirmed.
  • Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
  • Participants have a presence or relevant history of organic brain disorders.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
  • Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Eksperimentel: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Placebo komparator: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Manualized psychological support performed by facilitator.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Montgomery-Asberg Depression Scale (MADRS)
Tidsramme: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity.

The total score ranges 0-60, higher scores denote greater severity.

Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The Beck Depression Inventory - Second Edition (BDI-II)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.

Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0.

Day -1, Day 21, Day 42 and Day 84/End of Trial.
The Clinical Global Impression Scale (CGI-S)
Tidsramme: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.

The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index.

Only the severity of illness ang global improvement measures will be utilized for this trial.

Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:

  1. = Normal, not at all ill
  2. = Borderline ill
  3. = Mildly ill
  4. = Moderately ill
  5. = Markedly ill
  6. = Severely ill
  7. = Among the most extremely ill patients
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Tidsramme: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms.

Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows:

Scores represent:

0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety

Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities.

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.

Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70

Day -1, Day 21, Day 42 and Day 84/End of Trial.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studieleder: Felix Mazer, Cybin IRL Limited

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. december 2025

Primær færdiggørelse (Anslået)

7. juni 2027

Studieafslutning (Anslået)

9. august 2027

Datoer for studieregistrering

Først indsendt

21. januar 2025

Først indsendt, der opfyldte QC-kriterier

21. januar 2025

Først opslået (Faktiske)

27. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. oktober 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner